• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Optimizing treatment in PMN: efficacy and safety of rituximab-based regimens.

作者信息

Sahar Aliza, Ahsan Muhammad Umar, Nishat Zukhruf, Ishtiaq Shahmeer

机构信息

D.G. Khan Medical College, Dera Ghazi Khan, Punjab, Pakistan.

出版信息

Int Urol Nephrol. 2025 Jul 10. doi: 10.1007/s11255-025-04657-1.

DOI:10.1007/s11255-025-04657-1
PMID:40638026
Abstract
摘要

相似文献

1
Optimizing treatment in PMN: efficacy and safety of rituximab-based regimens.优化PMN的治疗：基于利妥昔单抗方案的疗效与安全性
Int Urol Nephrol. 2025 Jul 10. doi: 10.1007/s11255-025-04657-1.
2
Rituximab, tacrolimus, cyclophosphamide and cyclosporin in primary membranous nephropathy with nephrotic syndrome: comparison of safety profiles, effect on remission rate, 24-h urinary total protein, serum albumin, and serum creatinine levels using network meta-analysis.利妥昔单抗、他克莫司、环磷酰胺和环孢素治疗原发性膜性肾病伴肾病综合征：使用网状Meta分析比较安全性、对缓解率、24小时尿总蛋白、血清白蛋白和血清肌酐水平的影响
Int Urol Nephrol. 2025 May 8. doi: 10.1007/s11255-025-04549-4.
3
Immunosuppression therapy for idiopathic membranous nephropathy: systematic review with network meta-analysis.特发性膜性肾病的免疫抑制治疗：系统评价与网络荟萃分析。
J Nephrol. 2022 May;35(4):1159-1170. doi: 10.1007/s40620-022-01268-2. Epub 2022 Feb 23.
4
Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.成人肾病综合征中原发性膜性肾病的免疫抑制治疗。
Cochrane Database Syst Rev. 2021 Nov 15;11(11):CD004293. doi: 10.1002/14651858.CD004293.pub4.
5
Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy.原发性膜性肾病及其对利妥昔单抗耐药的治疗进展。
Front Immunol. 2022 May 4;13:859419. doi: 10.3389/fimmu.2022.859419. eCollection 2022.
6
Efficacy of low or heavy rituximab‑based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis.低剂量与高剂量利妥昔单抗方案治疗特发性膜性肾病的疗效及其与七种方案的比较：系统评价和网络荟萃分析。
Int Urol Nephrol. 2023 Mar;55(3):641-651. doi: 10.1007/s11255-022-03372-5. Epub 2022 Sep 25.
7
The efficacy and safety of ripertamab in the treatment of idiopathic membranous nephropathy: a retrospective multicenter cohort study.利珀他单抗治疗特发性膜性肾病的疗效和安全性：一项回顾性多中心队列研究。
Sci Rep. 2025 Jul 1;15(1):20567. doi: 10.1038/s41598-025-06046-1.
8
Efficacy and safety of a B-cell-driven rituximab regimen for the treatment of refractory idiopathic membranous nephropathy.一种B细胞驱动的利妥昔单抗方案治疗难治性特发性膜性肾病的疗效和安全性。
BMC Pharmacol Toxicol. 2025 Jul 4;26(1):131. doi: 10.1186/s40360-025-00954-8.
9
Urinary rituximab loss and rate of treatment failure in membranous nephropathy.膜性肾病中利妥昔单抗的尿丢失及治疗失败率
Nephrol Dial Transplant. 2025 Jul 7. doi: 10.1093/ndt/gfaf127.
10
Treatment of Membranous Nephropathy in Chinese Patients: Comparison of Rituximab and Intravenous Cyclophosphamide with Steroids.中国患者膜性肾病的治疗：利妥昔单抗与静脉注射环磷酰胺联合类固醇的比较。
Kidney Dis (Basel). 2024 Jul 29;10(5):359-368. doi: 10.1159/000540548. eCollection 2024 Oct.

本文引用的文献

1
Machine learning and transcriptomic analysis identify tubular injury biomarkers in patients with chronic kidney disease.机器学习和转录组分析可识别慢性肾病患者的肾小管损伤生物标志物。
Int Urol Nephrol. 2025 Jun 30. doi: 10.1007/s11255-025-04636-6.
2
Comparations of efficacy and safety of rituximab, calcineurin inhibitors and cyclophosphamide in primary membranous nephropathy: a single-center retrospective analysis.利妥昔单抗、钙调神经磷酸酶抑制剂和环磷酰胺治疗原发性膜性肾病的疗效及安全性比较：一项单中心回顾性分析
BMC Nephrol. 2024 Dec 24;25(1):473. doi: 10.1186/s12882-024-03912-4.
3
Different Dosage Regimens of Rituximab in Primary Membranous Nephropathy Treatment: A Systematic Review.
利妥昔单抗治疗原发性膜性肾病的不同给药方案：一项系统评价
Int J Nephrol Renovasc Dis. 2024 Oct 29;17:265-273. doi: 10.2147/IJNRD.S489455. eCollection 2024.
4
Exploring PLA2R and HLA in membranous nephropathy: A narrative review of pathogenic mechanisms and emerging therapeutic potentials.探索磷脂酶A2受体（PLA2R）和人类白细胞抗原（HLA）在膜性肾病中的作用：关于发病机制和新兴治疗潜力的叙述性综述
Int J Biol Macromol. 2024 Oct 2;280(Pt 1):136200. doi: 10.1016/j.ijbiomac.2024.136200.
5
A review of progress on complement and primary membranous nephropathy.补体与原发性膜性肾病研究进展述评。
Medicine (Baltimore). 2024 Jul 19;103(29):e38990. doi: 10.1097/MD.0000000000038990.
6
Efficacy of tacrolimus monotherapy in primary membranous nephropathy.他克莫司单药治疗原发性膜性肾病的疗效
Open Med (Wars). 2024 May 28;19(1):20240957. doi: 10.1515/med-2024-0957. eCollection 2024.
7
Efficacy of low or heavy rituximab‑based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis.低剂量与高剂量利妥昔单抗方案治疗特发性膜性肾病的疗效及其与七种方案的比较：系统评价和网络荟萃分析。
Int Urol Nephrol. 2023 Mar;55(3):641-651. doi: 10.1007/s11255-022-03372-5. Epub 2022 Sep 25.
8
Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy.近期原发性膜性肾病治疗的临床试验观察
Drugs. 2022 Feb;82(2):109-132. doi: 10.1007/s40265-021-01656-1. Epub 2021 Dec 21.